Meeting
2023 ASCO Genitourinary Cancers Symposium
Frailty and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Authors
Ekamjit Singh Deol
Saint Louis University School of Medicine, St. Louis, MO
Ekamjit Singh Deol , Suhong Luo , Kristen Marie Sanfilippo , Seth A Eisen , Martin W. Schoen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 71)
DOI
10.1200/JCO.2023.41.6_suppl.71
Abstract #
71
Poster Bd #
C2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Survival in Black and non-Black patients with metastatic prostate cancer.
First Author: Nina Cheranda
Poster
2021 Genitourinary Cancers Symposium
SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
First Author: Andrew Stangl
Poster
2019 Genitourinary Cancers Symposium
Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.
First Author: Megan Ann McNamara
Poster
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xiaolin Zhu